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Introduction
The ability of cells to migrate is a fundamental process in all 
living organisms. In vertebrates, cell migration is required for a 
wide array of biological processes that include embryogenesis, 
angiogenesis, epithelial wound healing, and immune responses. 
It is also involved in pathological conditions, such as arthritis, 
vascular disease, and neoplastic invasion (Ridley et al., 2003; 
Weijer, 2009). Cell migration has been well characterized   
in  Drosophila  melanogaster  and  Caenorhabditis  elegans, 
where it is indispensable for their development (Marston and 
Goldstein,  2006;  Montell,  2006).  In  addition,  in  the  social 
amoeba Dictyostelium discoideum, directed cell migration or 
chemotaxis is essential for cells to aggregate into a mound that 
will later differentiate into a multicellular organism (Bagorda 
and Parent, 2008). In order for cells to move, they must first   
acquire  a  polarized  morphology  where  F-actin  is  primarily   
enriched at the front and myosin II is assembled on the sides 
and at the back (Bagorda et al., 2006). Then, the polarized cells 
undergo a highly coordinated cycle of protrusions and retrac-
tions that are coupled with traction provided by the formation 
and release of adhesive contacts with the substrate (Le Clainche 
and Carlier, 2008). Not surprisingly, to accommodate the wide 
array of biological processes that depend on cell migration, the 
protrusion/retraction cycle is specifically regulated in different 
cell types. For example, slow-moving mesenchymal cells like 
fibroblasts exhibit strong cell–substrate adhesion forces that 
develop into mature contacts and give rise to slow migration 
speeds and almost no cell deformability (Friedl and Wolf, 2010; 
Parsons et al., 2010). On the other hand, fast-moving amoeboid 
cells  like  leukocytes  and  Dictyostelium  discoideum  exhibit 
weak and sparse adhesion to substrates, and, as a result, mi-
grate orders of magnitude faster and show remarkable plastic-
ity (Swaney et al., 2010). Regardless of the mode of migration 
used, during directed cell migration, cells must be able to deter-
mine where and when protrusions, retractions, and adhesions 
have to occur to migrate to the correct location. This is estab-
lished by extracellular cues that act through receptor tyrosine 
kinase (RTK) and G protein–coupled receptor (GPCR) signal 
transduction pathways, which provide spatio-temporal infor-
mation to direct the distribution of cytoskeletal elements and 
establish cell polarity (Citri and Yarden, 2006; Bagorda and 
Parent, 2008). Although Rho family GTP-binding proteins are 
important for regulating actin assembly to form protrusions, 
such as lamellipodia and filopodia, as well as force traction 
through actomyosin contractility, it is the upstream RTK and 
GPCR effectors that ultimately regulate the activity of Rho 
GTP-binding  proteins  (Jaffe  and  Hall,  2005;  Heasman  and   
Ridley, 2008; Berzat and Hall, 2010). In the past few years, our   
understanding of the signal transduction pathways that link re-
ceptors to Rho GTP-binding proteins has broadened to include 
products of phosphoinositide 3-kinase (PI3K), phospholipase 
A2 (PLA2), phospholipase C (PLC), adenylyl cyclase, and   
guanylyl cyclase (Bagorda and Parent, 2008; Stephens et al., 
2008; King and Insall, 2009; Wang, 2009; Swaney et al., 2010). 
More recently, another highly conserved signaling component, 
the Ser/Thr protein kinase TOR (target of rapamycin), has also 
been shown to transduce migration signals to cytoskeletal ele-
ments. In this review, we highlight data linking TOR to the   
regulation of cell migration and chemotaxis.
TORC1 and TORC2: evolutionarily 
conserved signaling complexes
TOR, initially identified in Saccharomyces cerevisiae (Heitman 
et al., 1991; Cafferkey et al., 1994), is a member of the phospha-
tidylinositol  kinase–related  kinase  (PIKK)  family,  which  in-
cludes ATM (ataxia-telangiectasia mutated), ATR (ATM and 
Rad3-related), DNA-dependent protein kinase (DNA-PK), and 
hSMG1  (suppressor  with  morphological  effect  on  genitalia) 
Cell migration is a fundamental process in a wide array of 
biological and pathological responses. It is regulated by 
complex signal transduction pathways in response to ex-
ternal cues that couple to growth factor and chemokine 
receptors. In recent years, the target of rapamycin (TOR) 
kinase, as part of either TOR complex 1 (TORC1) or TOR 
complex 2 (TORC2), has been shown to be an important 
signaling component linking external signals to the cyto-
skeletal machinery in a variety of cell types and organ-
isms. Thus, these complexes have emerged as key regulators 
of cell migration and chemotaxis.
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Signaling upstream of TOR complexes
TORC1 regulates cell growth and metabolism (Laplante and 
Sabatini,  2009)  and  the  pathways  regulating  the  activity  of 
mTORC1, which mostly focus on the GTPase-activating pro-
tein (GAP) tuberin, have been extensively studied. Tuberin is 
part of the hamartin/tuberin (TSC1/TSC2) complex and acts as 
a suppressor of mTORC1 activity (Inoki et al., 2002; Huang and 
Manning, 2008). It inhibits the GTP-binding protein Rheb (Ras 
homologue  enriched  in  brain),  which  directly  binds  to  the 
mTOR kinase domain and activates mTORC1 by an unknown 
mechanism (Garami et al., 2003; Inoki et al., 2003a; Tee et al., 
2003; Bai et al., 2007). The activity of tuberin is regulated   
by inputs from growth factors, nutrients, and hypoxia, and in-
volves Akt (Inoki et al., 2002), ERK1/2 (Ma et al., 2005), RSK 
(Roux et al., 2004), GSK3 (Inoki et al., 2006), AMP-dependent 
kinase, and HIF-1/REDD1 (Inoki et al., 2003b, 2006; Sofer et al., 
2005; Box 1).
In contrast to mTORC1, the signaling pathways that lead 
to mTORC2 activation are not well characterized. The TSC1/
TSC2 complex physically associates with mTORC2 and posi-
tively  regulates  its  activity  independently  of  the  Rheb-GAP   
activity of TSC1/TSC2 (Huang and Manning, 2008). However, 
in Drosophila melanogaster, Rheb has been reported to nega-
tively regulate dTORC2 through a dTORC1 and dS6K-dependent 
negative feedback loop (Yang et al., 2006b). In addition and 
similarly to mTORC1, phospholipase D and its metabolite 
phosphatidic acid appear to be critical for the formation of 
mTORC2 (Toschi et al., 2009). Also, Rac1 was shown to di-
rectly  interact  with  mTOR  and  regulate  both  mTORC1  and 
mTORC2 activity (Saci et al., 2011), and PIP3 (phosphatidylino-
sitol 3,4,5-trisphosphate), the product of PI3K, has been shown 
to directly stimulate mTORC2 kinase activity (Gan et al., 2011). 
However, reports are few and far between and no clear signaling 
pathway leading to the activation of mTORC2 has emerged. 
(Hoekstra, 1997; Abraham, 2001). These kinases possess Ser/
Thr protein kinase activity and do not display lipid kinase activity 
(Brunn et al., 1997; Burnett et al., 1998). TOR is a large (290 kD) 
multi-domain protein (Table I) that is structurally and functionally 
conserved from yeast to mammals. Its name arises from the fact 
that TOR binds the bacterial macrolide rapamycin when it is com-
plexed with FKBP12—a peptidyl prolyl isomerase (Heitman   
et al., 1991; Koltin et al., 1991). FKBP12–rapamycin binds to the 
FKBP12–rapamycin-binding domain of TOR (Table I), which in-
hibits TOR activity. Single amino acid substitutions in this domain 
block binding of FKBP12–rapamycin and generate a rapamycin-
resistant form of TOR (Heitman et al., 1991; Chen et al., 1995; 
McMahon et al., 2002).
TOR exists in two functionally distinct multiprotein com-
plexes named TOR complex 1 (TORC1) and TORC2. Each 
complex is highly conserved from yeast to mammals and is 
composed of specific core components and interactors (see Box 1 
and recent reviews on the topic; Jacinto and Lorberg, 2008; 
Zoncu et al., 2011). The precise role of each component of 
TORC1 and TORC2 has yet to be fully understood. In mTORC1, 
LST8 has been proposed to act as a signal receiver (Kim et al., 
2003), whereas Raptor functions as a scaffold for recruiting 
mTORC1 substrates, and PRAS40 and Deptor appear to be 
negative regulators (Fonseca et al., 2007; Wang et al., 2007;   
Peterson et al., 2009). In mTORC2, LST8 is required for the full 
catalytic kinase activity of mTOR and to a lesser extent, for 
structural stability of the complex (Guertin et al., 2006). Rictor 
and mSin1 interact with each other and also appear to be impor-
tant for the structural integrity of mTORC2 (Wullschleger et al., 
2005; Jacinto et al., 2006; Yang et al., 2006a). As in mTORC1, 
Deptor negatively regulates mTORC2 activity (Peterson et al., 
2009). The function of Protor, a Rictor-binding component that 
lacks obvious functional domains, remains to be determined 
(Pearce et al., 2007; Woo et al., 2007).
Table I.  Diagram depicting the structural domains and function of mTOR
Domain Function Reference
HEAT REPEAT
a Protein–protein interaction; membrane localization Andrade and Bork, 1995; Kunz et al., 2000;  
Perry and Kleckner, 2003
FAT
b Protein–protein interaction; kinase domain folding  
or organization
Bosotti et al., 2000
FRB
c Rapamycin sensitivity and substrate selectivity Cafferkey et al., 1994; Chen et al., 1995;  
Mcmahon et al., 2002
KINASE
d Ser–Thr protein kinase Brunn et al., 1997; Burnett et al., 1998
NRD
e Phosphorylated in response to insulin and growth factors Scott et al., 1998; Navé et al.,1999;  
Sekulić et al., 2000
FATC
f Kinase domain folding or organization Alarcon et al., 1999; Bosotti et al., 2000;  
Takahashi et al., 2000
aHuntingtin, elongation factor 3, protein phosphatase 2A, yeast PI3-kinase TOR1.
bFRAP (FKBP12-rapamycin-associated protein)/TOR, ATM (ataxia-telangiectasia), TRRAP (transactivation/tranformation domain-associated protein).
cFKBP12-rapamycin binding.
dCatalytic domain of PIKK.
eNegative regulatory domain.
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kinase C) family kinases (Jacinto and Lorberg, 2008; Pearce   
et al., 2010). AGC kinases are activated by phosphorylation of a 
conserved Ser/Thr residue in their activation loop (also called   
T-loop), which can occur via autophosphorylation or through other 
protein kinases such as PDK1 (3-phosphoinositide–dependent 
protein kinase 1) (Mora et al., 2004). In addition to phosphory-
lation at the T-loop motif, several AGC kinases are also phosphory-
lated at Ser or Thr residues within their hydrophobic motif in the 
C terminus (Jacinto and Lorberg, 2008; Alessi et al., 2009). From 
yeast to mammals, TOR complexes have been shown to phos-
phorylate a subset of AGC kinases at a conserved noncatalytic 
residue within their C-terminal hydrophobic motif, which con-
sists of Phe-X-X-Phe-Ser/Thr-Tyr (Jacinto and Lorberg, 2008; 
Alessi et al., 2009). mTORC1 phosphorylates the hydrophobic 
motif of S6K1, whereas mTORC2 phosphorylates the hydropho-
bic motif of SGK1, Akt, and PKC (Pearson et al., 1995; Sarbassov 
et al., 2004, 2005; García-Martínez and Alessi, 2008). Similarly, 
in Dictyostelium discoideum, TORC2 phosphorylates the Akt   
homologues PKBA and PKBR1 (Kamimura et al., 2008).
A wide array of non-AGC kinases, transcription factors, 
and other regulators act as effectors of TOR in yeast and mammals 
On the other hand, an extensive body of work in Dictyostelium 
discoideum  has  revealed  how  chemotactic  signals  mediated 
through GPCRs specifically regulate TORC2 activity through G 
proteins and Ras signals, independently of PI3K (Lee et al., 
2005; Kamimura et al., 2008; Cai et al., 2010). In this organism, 
a Ras signaling complex, composed of two Ras GEFs (guanine 
exchange factor; Aimless and RasGEFH), a protein phospha-
tase (PP2A), and a scaffold designated Sca1, regulates the acti-
vation  of  RasC,  which  controls  the  chemoattractant-induced 
activation of TORC2 at the leading edge of chemotaxing cells 
(Kamimura et al., 2008; Charest et al., 2010). In addition, the 
membrane localization of the Sca1–RasGEF–PP2A complex is 
regulated through the Akt(PKB)-dependent phosphorylation of 
Sca1, which provides negative feedback to RasC and TORC2 
(Charest et al., 2010). In this system, therefore, a clear path can 
be traced from a GPCR to the spatio-temporal activation of 
TORC2, which is important in regulating chemotaxis.
Signaling downstream of TOR complexes
The best-characterized TOR substrates include a subgroup of   
related AGC (cAMP-dependent, cGMP-dependent, and protein 
Box 1.  Conserved core components and interactors of TORC1 and TORC2 in S. cerevisiae, D. discoideum, and mammalsJCB • VOLUME 194 • NUMBER 6 • 2011   818
regulates growth factor–induced cell migration, as rapamycin 
treatment  inhibits  growth  factor–induced  cell  migration  of  a 
wide array of cell lines (Attoub et al., 2000; Berven et al., 2004; 
Wong et al., 2004; Wan et al., 2005; Liu et al., 2006, 2008, 
2010b; Zhou and Wong, 2006). Interestingly, the rapamycin- 
mediated inhibition of IGF-I–stimulated motility of Rh30 (rhab-
domyosarcoma) cells can be prevented by either the expression 
of a rapamycin-resistant mutant of mTOR (mTORrr), a constitu-
tively active version of S6K1, or the down-regulation of 4E-BP1 
(Liu et al., 2006). Therefore, mTORC1 can regulate cell motility 
via both S6K1 and 4E-BP1 pathways.
Although the mechanisms by which mTORC1 regulates 
cell migration remain to be determined, a few reports provide 
evidence that S6K1 controls cell migration by regulating: (a)   
F-actin reorganization, (b) focal adhesion formation, (c) tissue 
remodeling through the proteolytical digestion of extracellular 
matrix via up-regulation of MMP-9 (matrix metalloproteinase 9; 
Vaillant et al., 2003; Khandoga et al., 2006), and (d) Rho ex-
pression and activity (Fig. 1). Activated mTOR and S6K1 along 
with PI3K, Akt1, and PDK1 are enriched in actin arcs, a caveo-
lin-enriched cytoskeletal structure located at the leading edge of 
migrating Swiss 3T3 cells, and mTOR and p70S6K activation 
is required for actin arc formation (Berven et al., 2004). On the 
other hand, in Rh30 cells, down-regulation of Raptor or S6K1 
suppresses IGF-I–stimulated tyrosine phosphorylation of FAK 
and paxillin (Liu et al., 2008). Thus, the kinase activity of S6K1 
seems essential for IGF-I–stimulated focal adhesion formation. 
In SKOV-3 and CaOV-3 ovarian cancer cells, the expression of 
a constitutively active form of S6K1 induces MMP-9 expres-
sion and enhances its activity, which is independent of de novo 
protein synthesis as it is not affected by cycloheximide treat-
ment (Zhou and Wong, 2006). In contrast, the effects of 4E-
BP1 on cell migration appear to be mediated through changes in 
mRNA  translation  and  protein  synthesis.  In  activated  CD4
+   
T cells, the chemokine CCL5-induced mTOR-dependent phos-
phorylation  of  4E-BP1  ultimately  leads  to  its  release  from 
eIF4E. eIF4E associates with the scaffold proteins eIF4G and 
eIF4A and forms the eIF4F heterotrimeric initiation complex, 
which initiates mRNA translation and protein synthesis of a 
wide array of targets, including cyclinD1 and MMP-9 (Murooka   
et al., 2008). Pretreatment with rapamycin or cycloheximide 
abolishes CCL5-induced up-regulation of cyclin D1 and MMP-9 
while also significantly reducing CCL5-mediated T cell chemo-
taxis (Murooka et al., 2008). Thus, S6K1 and 4E-BP1 seem to 
independently regulate the expression and activity of MMP-9 
during migration. Finally, recent studies suggest that rapamycin 
inhibits the expression and activity of the small GTP-binding 
proteins RhoA, Cdc42, and Rac1 in a panel of tumor cells includ-
ing Rh30, HeLa (cervical cancer), PC-3 (prostate cancer), Rh1 
(Ewing sarcoma), and U373 (glioblastoma) cells (Liu et al., 2010b). 
Similar effects were observed by the expression of constitutively 
active  4EBP1-5A  or  the  down-regulation  of  S6K1.  Notably, 
overexpression of constitutively active RhoA, but not Rac1 and 
Cdc42, prevented the rapamycin-mediated inhibition of lamelli-
podia formation and cell migration (Liu et al., 2010b). Thus, in 
these cell lines, mTORC1-mediated regulation of cell motility 
depends on RhoA in a 4E-BP1– and S6K1-dependent fashion.
(Box 1). Notably, mTORC1 controls the phosphorylation state 
of 4E-BP1, an important translation initiation machinery com-
ponent (Haghighat et al., 1995; Beretta et al., 1996; Kim et al., 
2002). Phosphorylation of 4E-BP1 induces its dissociation   
from eIF4E and promotes the initiation of protein translation 
(Haghighat et al., 1995)—a main effect of mTORC1 activation. 
In  addition,  mTORC1  directly  phosphorylates  and  inactivates 
MAF1 (a key repressor or RNA polymerase II transcription) 
and contributes to RNA polymerase III–dependent transcription 
(Kantidakis et al., 2010; Michels et al., 2010; Shor et al., 2010). 
Interestingly, mTORC1 also regulates microtubule dynamics by 
physically interacting with CLIP-170, the human homologue of 
yeast Bik1p, which belongs to a family of conserved microtubule-
associated proteins (Choi et al., 2000; Jiang and Yeung, 2006). 
Phosphorylation of CLIP-170 by mTORC1 positively regulates the 
association of CLIP-170 with microtubules, which enhances their 
assembly, elongation, and stability. Finally, a few reports have sug-
gested the existence of cross talk between mTORC1 and mTORC2, 
as S6K1 has been reported to phosphorylate Rictor and positively 
regulate mTORC2. Although this phosphorylation event does not 
affect mTORC2 integrity or in vitro kinase activity, it causes an in-
crease in 14-3-3 binding to Rictor and mTORC2-dependent phos-
phorylation of Akt on S473 (Dibble et al., 2009; Julien et al., 2010; 
Treins et al., 2010). As Akt can positively regulate mTORC1 (see 
previous section), these findings underscore a potential cross talk 
between mTORC1 and mTORC2.
TORC1 and cell migration
Studies using rapamycin have implicated mTORC1 as a regu-
lator of mammalian cell migration under normal conditions as 
well as in the context of tumor metastasis (Fig. 1). In aortic 
smooth  muscle  cells,  rapamycin  inhibits  fibronectin-induced   
activation of mTORC1 and S6K1 and markedly diminishes che-
motaxis of smooth muscle cells toward fibronectin (Poon et al., 
1996; Sakakibara et al., 2005), thereby implicating mTORC1   
in  matrix  protein–induced  cell  migration.  Further,  mTORC1 
Figure 1.  mTORC1 and cell migration. S6K1 and 4E-BP1 control cell mo-
tility by regulating (1) F-actin reorganization, (2) focal adhesion formation, 
(3) MMP-9 up-regulation (4) Rho expression and activity, and (5) VEGF 
and TGF- expression in various cell types.819 TOR signaling during migration • Liu and Parent
Although no obvious alterations in the actin cytoskeleton is   
observed in embryonic fibroblasts derived from Rictor knockout 
mice (Guertin et al., 2006; Shiota et al., 2006), siRNA-mediated 
knockdown of mTOR, Rictor, or mLST8 prevents actin polym-
erization and cell spreading in NIH3T3 fibroblasts (Jacinto et al., 
2004). In contrast, in HeLa cells, lentivirus shRNA-mediated 
Rictor and mTOR knockdown leads to increased stress fiber 
and  cytoplasmic  paxillin  patch  formation  (Sarbassov  et  al., 
2004).  Together,  these  studies  highlight  the  possibility  that 
mTORC2 may have distinct effects on the actin cytoskeleton in 
different cell types.
The  molecular  mechanism  by  which  TORC2  mediates   
actin reorganization has been extensively studied in Saccharo-
myces cerevisiae where the protein kinases PKC1, YPK2 (yeast 
protein kinase 2), and SLM (synthetic lethal with Mss4) are   
involved (Fig. 2). In these cells, TOR2 activates the GTP-binding 
protein Rho1 through the GTP exchange factor Rom2, which 
in turn triggers the activation of PKC1. Active PKC1 controls 
the  polarization  of  the  actin  cytoskeleton  via  the  MAP   
kinase cascade (Kamada et al., 1995, 1996; Schmidt et al., 1997;   
Loewith  et al., 2002), and up-regulation of Rho1, PKC1, or PKC1- 
controlled MAP kinase suppresses the actin defect of tor2  
mutant (Helliwell et al., 1998). YPK2 is an AGC kinase that is 
directly activated by TORC2 via phosphorylation on Ser641 and 
Thr659 (Kamada et al., 2005). YPK2 activity is greatly reduced 
in tor2 mutants and overexpression of a constitutively active 
mutant of YPK2 restores MAP kinase activation and suppresses 
the  actin  cytoskeleton  organization  defects  of  tor2  mutants   
(Kamada et al., 2005). SLM1 and SLM2, homologous pleckstrin 
homology (PH) domain–containing proteins that bind to phos-
phatidylinositol-4,5-bisphosphate (PIP2), physically interact 
with AVO2 and BIT61 and mediate TORC2 signaling to the   
actin cytoskeleton (Fadri et al., 2005). Overexpression of PKC1, 
but not activated forms of the MAP kinase components can 
mTORC1 has also been implicated as a regulator of tumor 
cell metastasis and angiogenesis in a variety of cancers (Guba   
et al., 2002; Luan et al., 2003; Boffa et al., 2004; Wan et al., 2005; 
Kobayashi et al., 2007). The effects of rapamycin on metastasis 
have been linked to changes in VEGF, a key regulator of both 
metastasis and angiogenesis (Ferrara, 2002; Turner et al., 2003). 
Rapamycin  treatment  significantly  inhibits  the  secretion  of 
VEGF both in cultured mouse colon adenocarcinoma cells as 
well as adenocarcinoma tumor-bearing mice (Guba et al., 2002). 
In B13LM cells (a lymphatic metastasis-prone pancreatic tumor 
cell line), dose-dependent reductions of VEGF-A and VEGF-C 
expression were observed after rapamycin treatment (Kobayashi 
et al., 2007). Further, in renal and nonsmall lung cancer cells, 
after treatment with rapamycin, a reduction in both VEGF-A 
and TGF- expression were observed at both the mRNA and 
protein levels (Luan et al., 2003; Boffa et al., 2004). Moreover, 
treatment of tumor-bearing mice with rapamycin gives rise to a 
significant reduction in the circulating levels of TGF- (Boffa 
et al., 2004). These mechanistic studies suggest that mTORC1-
regulated  tumor  metastasis  and  angiogenesis  are  associated 
with, at least in part, the production of VEGF and TGF-.
TORC2 and cell migration
TORC2 regulates cytoskeleton organization. Accu-
mulating evidence indicates that TORC2 is a key regulator of 
the actin cytoskeleton (Fig. 2). In Saccharomyces cerevisiae, 
TORC2 is required for the cell cycle–dependent polarization of 
the actin cytoskeleton (Schmidt et al., 1996). In Dictyostelium 
discoideum, knockout of individual TORC2 components leads 
to the loss of cell polarity and the random extension of pseudo-
pods from multiple points of the cells (Chen et al., 1997; Lee   
et al., 1999, 2005). In human neutrophils, inhibition of mTORC2 
function by Rictor knockdown also leads to cell polarity defects 
and uniform cortical F-actin accumulation (Liu et al., 2010a). 
Figure 2.  TORC2 regulates cytoskeleton organization and cell migration in yeast, amoebae, and mammalian cells. (A) In Saccharomyces cerevisiae, TOR2 
regulates actin organization and polarization through PKC1 and MAPK pathways. (B) In Dictyostelium discoideum, GPCRs specifically regulate TORC2 
through a Ras signaling complex, which controls actin assembly and polarization as well as the synthesis of cAMP and the activation of PKA. (C) In mam-
malian cells, mTORC2 also regulates Rac and PKC and plays a key role in neutrophil chemotaxis by independently regulating F-actin polarization and 
myosin II phosphorylation. In endothelial cells, mTORC2 decreases p27
Kip1 levels, which results in high RhoA activity and increased chemotaxis.JCB • VOLUME 194 • NUMBER 6 • 2011   820
cyclase activity defects during aggregation (Kamimura et al., 
2008; Cai et al., 2010). Once activated, PKBR1 phosphorylates 
several substrates, including Sca1, Talin, two Ras GEFs, and a 
Rho GAP (Kamimura et al., 2008; Charest et al., 2010). Although 
P-Sca1 has been shown to negatively regulate RasC activity, the 
precise role of the phosphorylation of other PKBR1 substrates 
during  chemotaxis  remains  to  be  determined.  Together,  these 
studies establish a pathway arising from GPCRs, through G pro-
teins and a Ras signaling complex, which activates TORC2 to regu-
late cell polarity, actin assembly, and adenylyl cyclase activity.
mTORC2 also plays a key role during neutrophil chemo-
taxis by independently regulating F-actin polarization and myo-
sin II (MyoII) phosphorylation. Rictor knockdown or prolonged 
rapamycin treatment strongly inhibits neutrophil polarity and 
chemotaxis to the GPCR ligands fMLP (N-formyl-methionine-
leucine-phenylalanine) and LTB4 (leukotriene B4), as well as 
cAMP production (Liu et al., 2010a). However, in contrast to 
Dictyostelium discoideum, the effects of mTORC2 are not me-
diated through Akt (PKB). Instead, and in accordance with 
findings in yeast and mammalian systems, it appears that PKC 
is mediating part of mTORC2’s effects by regulating adenylyl 
cyclase  activity  and  cAMP  production.  Cyclic AMP  then 
regulates MyoII assembly through a RhoA/ROCK-dependent 
pathway.  Interestingly,  although  mTORC1  is  required  for 
GM-CSF (granulocyte macrophage colony-stimulating fac-
tor)–induced neutrophil migration (Gomez-Cambronero, 2003; 
Liu et al., 2010a), it is dispensable for fMLP- and LTB4-mediated 
chemotaxis (Liu et al., 2010a). Thus, mTORC2 appears to 
specifically  regulate  neutrophil  chemotaxis  toward  GPCR   
ligands. Similarly to neutrophils, in mouse bone marrow– 
derived mast cells, the GPCR-mediated chemotaxis via pros-
taglandin  E2  (PGE2)  receptors  is  specifically  dependent  on 
mTORC2 (Kuehn et al., 2011). Rictor-targeted shRNA results 
in a significant attenuation in PGE2-mediated chemotaxis, yet 
the selective inhibition of mTORC1 by rapamycin treatment 
or by Raptor knockdown fails to decrease PGE2-mediated   
chemotaxis in these cells.
Rictor levels are elevated in a wide array of glioma cell 
lines and primary glioma tumor cells (Masri et al., 2007), as well 
as in invasive breast ductal carcinomas (Zhang et al., 2010). Fur-
thermore, overexpression or knockdown of Rictor in glioma cell 
lines results in either increased or decreased cell migration, 
(Masri et al., 2007), although a separate group reported that 
mTORC2 negatively regulates invasion in two glioma cell lines 
(Das et al., 2011). Intriguingly, Rictor could mediate its effects on 
cell  migration  in  an  mTORC2-independent  fashion.  Indeed, 
Zhang et al. (2010) present evidence suggesting that the inhibi-
tion of migration observed in MDA-MB-231 breast cancer cells 
with reduced Rictor levels is mediated independently of mTORC2 
through a direct interaction with PKC-. They show that mSin1 
knockdown does not alter chemotaxis of MDA-MB-231 cells, 
nor does it affect Rictor–PKC- interaction (Zhang et al., 2010). 
In this context, Rictor can form a complex with the integrin-
linked kinase and regulate Akt phosphorylation in an mTORC2-
independent fashion (McDonald et al., 2008). It will be interesting 
to see if these mTORC2-independent effects of Rictor impact 
mTORC2 or even mTORC1 signals.
restore proper actin filament assembly and actin polarization in 
slm1/slm2-null cells (Fadri et al., 2005). Thus, SLM signaling 
likely  involves  a  MAP  kinase–independent  PKC1  signaling 
branch or may act in a pathway that has an overlapping function 
with PKC1.
Consistent with studies from yeast, mTORC2 also regu-
lates the activation of PKC- and Rac (Fig. 2). In HeLa cells, 
PKC- activity is reduced in Rictor and mTOR knockdown cells 
and the morphology of the actin cytoskeleton in PKC- knock-
down  cells  is  similar  to  that  of  Rictor  knockdown  cells   
(Sarbassov et al., 2004). In NIH3T3 cells, knockdown of mTOR, 
LST8, or Rictor results in a 20–30% decrease Rac1 activity. In 
addition, the expression of an active form of Rac1 or RhoA re-
stores the formation of membrane ruffles, lamellipodia, and stress 
fibers in mTOR, mLST8, or Rictor knockdown cells (Jacinto   
et al., 2004). The mechanism by which this occurs could involve 
P-Rex1 and P-Rex2 (PIP3-dependent Rac exchange factor), Rac 
GEFs linking GPCRs, G, and PI3K signaling to Rac activa-
tion. In HeLa cells, exogenously expressed P-Rex1 and P-Rex2 
interact with mTOR through their tandem DEP (disheveled, 
EGL-10,  and  pleckstrin)  domain  (Hernández-Negrete  et  al., 
2007). Moreover, P-Rex1 appears to link mTOR signaling to 
Rac activation, as cells expressing dominant-negative con-
structs or shRNA-mediated knockdown of P-Rex1 specifically   
decrease  mTORC2-dependent  leucine-induced  activation  of 
Rac (Hernández-Negrete et al., 2007). As the yeast Rom2 also 
harbors a DEP domain, P-Rex may represent the mammalian 
orthologue of Rom2.
TORC2  regulates  cell  migration. The ability of 
mTORC2 to regulate actin networks suggests that it may be in-
volved in regulating cell migration. Although several studies on 
glioblastoma cells lines, Rh30, HeLa, and endothelial cells have 
implicated mTORC2 as a positive regulator of cell motility (Liu 
et al., 2006; Hernández-Negrete et al., 2007; Masri et al., 2007; 
Dada et al., 2008), in-depth mechanistic insight has come from 
studies in Dictyostelium discoideum (Fig. 2). In this system, the 
binding of the chemoattractant cAMP to specific GPCRs leads to 
the activation of signal transduction pathways that regulate gene 
expression, the production and degradation of cAMP, and che-
motaxis (Bagorda et al., 2006). Null mutations of TORC2 com-
ponents give rise to cells with severe cell polarity defects, reduced 
chemotactic speeds and directionality, and the inability to acti-
vate adenylyl cyclase (Chen et al., 1997; Lee et al., 1999, 2005). 
Through a Ras signaling complex that activates RasC, chemoat-
tractant addition stimulates TORC2 specifically at the leading 
edge of chemotaxing cells (Cai et al., 2010; Charest et al., 2010). 
TORC2 phosphorylates PKBA as well as PKBR1. Unlike PKBA, 
which harbors a PH domain, PKBR1 lacks a PH domain and is 
constitutively anchored to the plasma membrane (independently 
of PI3K activity) via a Myr site at its N terminus (Meili et al., 
2000; Kamimura et al., 2008). Interestingly, PKBR1 appears to 
be  the  major  effector  of  TORC2  during  chemotaxis  toward 
cAMP, as cells lacking PKBA show mild chemotaxis defects and 
retain a normal phosphorylation pattern of PKB substrates in ag-
gregating cells. On the other hand, cells lacking PKBR1, or com-
ponents of the Ras signaling complex, have a similar phenotype 
as TORC2 mutants, exhibiting both chemotaxis and adenylyl 821 TOR signaling during migration • Liu and Parent
We thank Drs. Philippe Afonzo and Michael Weiger for their critical input.
This work was supported by the Intramural Research Program of the Center 
for Cancer Research, National Cancer Institute, National Institutes of Health.
Submitted: 17 February 2011
Accepted: 25 August 2011
References
Abraham,  R.T.  2001.  Cell  cycle  checkpoint  signaling  through  the  ATM 
and  ATR  kinases.  Genes  Dev.  15:2177–2196.  http://dx.doi.org/10 
.1101/gad.914401
Alarcon, C.M., J. Heitman, and M.E. Cardenas. 1999. Protein kinase activity   
and identification of a toxic effector domain of the target of rapamycin 
TOR proteins in yeast. Mol. Biol. Cell. 10:2531–2546.
Alessi, D.R., L.R. Pearce, and J.M. García-Martínez. 2009. New insights into 
mTOR  signaling:  mTORC2  and  beyond.  Sci.  Signal.  2:pe27.  http://
dx.doi.org/10.1126/scisignal.267pe27
Andrade, M.A., and P. Bork. 1995. HEAT repeats in the Huntington’s disease 
protein. Nat. Genet. 11:115–116. http://dx.doi.org/10.1038/ng1095-115
Attoub,  S.,  V.  Noe,  L.  Pirola,  E.  Bruyneel,  E.  Chastre,  M.  Mareel,  M.P. 
Wymann, and C. Gespach. 2000. Leptin promotes invasiveness of kidney 
and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-
dependent  signaling  pathways.  FASEB  J.  14:2329–2338.  http://dx.doi 
.org/10.1096/fj.00-0162
Bagorda, A., and C.A. Parent. 2008. Eukaryotic chemotaxis at a glance. J. Cell 
Sci. 121:2621–2624. http://dx.doi.org/10.1242/jcs.018077
Bagorda, A., V.A. Mihaylov, and C.A. Parent. 2006. Chemotaxis: moving for-
ward and holding on to the past. Thromb. Haemost. 95:12–21.
Bai, X., D. Ma, A. Liu, X. Shen, Q.J. Wang, Y. Liu, and Y. Jiang. 2007. Rheb 
activates  mTOR  by  antagonizing  its  endogenous  inhibitor,  FKBP38. 
Science. 318:977–980. http://dx.doi.org/10.1126/science.1147379
Beretta, L., A.C. Gingras, Y.V. Svitkin, M.N. Hall, and N. Sonenberg. 1996. 
Rapamycin  blocks  the  phosphorylation  of  4E-BP1  and  inhibits  cap- 
dependent initiation of translation. EMBO J. 15:658–664.
Berven, L.A., F.S. Willard, and M.F. Crouch. 2004. Role of the p70(S6K) path-
way in regulating the actin cytoskeleton and cell migration. Exp. Cell Res. 
296:183–195. http://dx.doi.org/10.1016/j.yexcr.2003.12.032
Berzat, A., and A. Hall. 2010. Cellular responses to extracellular guidance cues. 
EMBO J. 29:2734–2745. http://dx.doi.org/10.1038/emboj.2010.170
Boffa, D.J., F. Luan, D. Thomas, H. Yang, V.K. Sharma, M. Lagman, and M. 
Suthanthiran. 2004. Rapamycin inhibits the growth and metastatic pro-
gression of non-small cell lung cancer. Clin. Cancer Res. 10:293–300. 
http://dx.doi.org/10.1158/1078-0432.CCR-0629-3
Bosotti, R., A. Isacchi, and E.L. Sonnhammer. 2000. FAT: a novel domain in 
PIK-related  kinases.  Trends  Biochem.  Sci.  25:225–227.  http://dx.doi 
.org/10.1016/S0968-0004(00)01563-2
Brunn, G.J., C.C. Hudson, A. Sekulić, J.M. Williams, H. Hosoi, P.J. Houghton, 
J.C.  Lawrence  Jr.,  and  R.T.  Abraham.  1997.  Phosphorylation  of  the 
translational repressor PHAS-I by the mammalian target of rapamycin. 
Science. 277:99–101. http://dx.doi.org/10.1126/science.277.5322.99
Burnett, P.E., R.K. Barrow, N.A. Cohen, S.H. Snyder, and D.M. Sabatini. 1998. 
RAFT1 phosphorylation of the translational regulators p70 S6 kinase 
and 4E-BP1. Proc. Natl. Acad. Sci. USA. 95:1432–1437. http://dx.doi 
.org/10.1073/pnas.95.4.1432
Cafferkey, R., M.M. McLaughlin, P.R. Young, R.K. Johnson, and G.P. Livi. 
1994. Yeast TOR (DRR) proteins: amino-acid sequence alignment and 
identification  of  structural  motifs.  Gene.  141:133–136.  http://dx.doi 
.org/10.1016/0378-1119(94)90141-4
Cai,  H.,  S.  Das,  Y.  Kamimura,  Y.  Long,  C.A.  Parent,  and  P.N.  Devreotes. 
2010. Ras-mediated activation of the TORC2-PKB pathway is critical 
for  chemotaxis.  J.  Cell  Biol.  190:233–245.  http://dx.doi.org/10.1083/ 
jcb.201001129
Charest, P.G., Z. Shen, A. Lakoduk, A.T. Sasaki, S.P. Briggs, and R.A. Firtel. 
2010.  A  Ras  signaling  complex  controls  the  RasC-TORC2  pathway 
and directed cell migration. Dev. Cell. 18:737–749. http://dx.doi.org/10 
.1016/j.devcel.2010.03.017
Chen, J., X.F. Zheng, E.J. Brown, and S.L. Schreiber. 1995. Identification of 
an  11-kDa  FKBP12-rapamycin-binding  domain  within  the  289-kDa 
FKBP12-rapamycin-associated protein and characterization of a critical 
serine residue. Proc. Natl. Acad. Sci. USA. 92:4947–4951. http://dx.doi 
.org/10.1073/pnas.92.11.4947
Chen,  M.Y.,  Y.  Long,  and  P.N.  Devreotes.  1997.  A  novel  cytosolic  regulator, 
Pianissimo, is required for chemoattractant receptor and G protein-mediated 
activation of the 12 transmembrane domain adenylyl cyclase in Dictyostelium. 
Genes Dev. 11:3218–3231. http://dx.doi.org/10.1101/gad.11.23.3218
Although rapamycin FKBP12 cannot bind to mTORC2, 
prolonged rapamycin treatment inhibits mTORC2 function by 
sequestering mTOR and interfering with mTORC2 assembly in 
some cell lines (Sarbassov et al., 2006). Surprisingly, prolonged 
but not short-term rapamycin treatment inhibits endothelial cell 
(Sun et al., 2001) as well as mesangial cell migration (Daniel   
et  al.,  2004)  through  the  cyclin-dependent  kinase  inhibitor 
(p27
Kip1). A recent study revealed that siRNA knockdown of 
Rictor increases p27
Kip1 levels, resulting in the inhibition of 
RhoA activity and inhibition of VEGF-mediated endothelial 
chemotaxis (Moss et al., 2010). These findings provide novel 
mechanistic insight into the role of cyclin-dependent kinase pro-
teins outside the nucleus (Denicourt and Dowdy, 2004).
Perspectives
Although it is becoming clear that both TOR complex 1 and 2 
regulate cytoskeletal networks and cell migration, we are far from 
understanding the mechanism by which this takes place. This is 
primarily due to the complexity of the TOR signaling cascades 
and their impact on a wide array of effectors, as well as to the dis-
tinct migratory behaviors exhibited by different cells and the che-
motactic input (i.e., RTK vs. GPCR). In this context, it will be 
very interesting to see if the TORC2-mediated effects on chemo-
taxis of amoeboid-like cells extend to other cell types with distinct 
cellular architecture and motility behaviors. Indeed, in contrast to 
mesenchymal cells such as fibroblasts, where microtubules pri-
marily extend to the front (Kupfer et al., 1982; Gundersen and 
Bulinski, 1988), amoeboid-like cells such Dictyostelium discoi-
deum, neutrophils, and migrating lymphocytes have an extensive 
microtubule network at their back and the microtubule organizing 
center is positioned behind the nucleus (Ratner et al., 1997; Eddy 
et al., 2002; Kriebel et al., 2008). This distinct cellular architecture 
underscores the dramatically different mechanisms regulating the 
motility machinery in these two cell types. Indeed, in contrast to 
neutrophils where RhoA activity is restricted to the back (Wong   
et al., 2007), high RhoA activity has been reported at the leading 
edge of HeLa and MDCK cells (Kurokawa and Matsuda, 2005) 
and Rho signaling has been shown to stabilize microtubules at the 
leading edge of fibroblast cells (Palazzo et al., 2004). It is there-
fore foreseeable that distinct TOR signals mediate distinct effects 
on cell types with very different cytoskeletal organizations and 
motility machineries. This could have interesting consequences 
during metastasis, where dynamic epithelial-to-mesenchymal as 
well as mesenchymal-to-amoeboid transitions dramatically alter 
the motility behavior of cells (Friedl and Wolf, 2010). Impor-
tantly, as it has been observed with the PI3K pathway (Ferguson 
et al., 2007), the effects of TOR signaling may also be dependent 
on the microenvironment, which adds another layer of complexity 
to the picture. In any case, to move the field forward, it is impor-
tant to use approaches that precisely target TORC1 or TORC2. 
Although rapamycin certainly represents a powerful tool in the 
TOR field, in an increasing number of cells, long-term treatment 
with rapamycin also inhibits TORC2 (Sarbassov et al., 2006; Liu 
et al., 2010a; Moss et al., 2010). We have yet to fully appreciate 
the extent by which TOR complexes regulate a wide array of pro-
cesses, including cell migration, and the future will undoubtedly 
continue to bring unexpected insight.JCB • VOLUME 194 • NUMBER 6 • 2011   822
Heitman, J., N.R. Movva, and M.N. Hall. 1991. Targets for cell cycle arrest 
by the immunosuppressant rapamycin in yeast. Science. 253:905–909. 
http://dx.doi.org/10.1126/science.1715094
Helliwell, S.B., A. Schmidt, Y. Ohya, and M.N. Hall. 1998. The Rho1 ef-
fector Pkc1, but not Bni1, mediates signalling from Tor2 to the actin 
cytoskeleton. Curr. Biol. 8:1211–1214. http://dx.doi.org/10.1016/S0960- 
9822(07)00511-8
Hernández-Negrete, I., J. Carretero-Ortega, H. Rosenfeldt, R. Hernández-García, 
J.V. Calderón-Salinas, G. Reyes-Cruz, J.S. Gutkind, and J. Vázquez-Prado. 
2007. P-Rex1 links mammalian target of rapamycin signaling to Rac acti-
vation and cell migration. J. Biol. Chem. 282:23708–23715. http://dx.doi 
.org/10.1074/jbc.M703771200
Hoekstra, M.F. 1997. Responses to DNA damage and regulation of cell cycle 
checkpoints by the ATM protein kinase family. Curr. Opin. Genet. Dev. 
7:170–175. http://dx.doi.org/10.1016/S0959-437X(97)80125-6
Huang, J., and B.D. Manning. 2008. The TSC1-TSC2 complex: a molecular 
switchboard controlling cell growth. Biochem. J. 412:179–190. http://
dx.doi.org/10.1042/BJ20080281
Inoki, K., Y. Li, T. Zhu, J. Wu, and K.L. Guan. 2002. TSC2 is phosphorylated 
and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 
4:648–657. http://dx.doi.org/10.1038/ncb839
Inoki, K., Y. Li, T. Xu, and K.L. Guan. 2003a. Rheb GTPase is a direct tar-
get of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 
17:1829–1834. http://dx.doi.org/10.1101/gad.1110003
Inoki, K., T. Zhu, and K.L. Guan. 2003b. TSC2 mediates cellular energy re-
sponse to control cell growth and survival. Cell. 115:577–590. http://
dx.doi.org/10.1016/S0092-8674(03)00929-2
Inoki, K., H. Ouyang, T. Zhu, C. Lindvall, Y. Wang, X. Zhang, Q. Yang, C. 
Bennett, Y. Harada, K. Stankunas, et al. 2006. TSC2 integrates Wnt 
and  energy  signals  via  a  coordinated  phosphorylation  by  AMPK 
and  GSK3  to  regulate  cell  growth.  Cell.  126:955–968.  http://dx.doi 
.org/10.1016/j.cell.2006.06.055
Jacinto, E., and A. Lorberg. 2008. TOR regulation of AGC kinases in yeast 
and  mammals.  Biochem.  J.  410:19–37.  http://dx.doi.org/10.1042/ 
BJ20071518
Jacinto, E., R. Loewith, A. Schmidt, S. Lin, M.A. Rüegg, A. Hall, and M.N. 
Hall. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton 
and is rapamycin insensitive. Nat. Cell Biol. 6:1122–1128. http://dx.doi 
.org/10.1038/ncb1183
Jacinto, E., V. Facchinetti, D. Liu, N. Soto, S. Wei, S.Y. Jung, Q. Huang, J. 
Qin, and B. Su. 2006. SIN1/MIP1 maintains rictor-mTOR complex in-
tegrity and regulates Akt phosphorylation and substrate specificity. Cell. 
127:125–137. http://dx.doi.org/10.1016/j.cell.2006.08.033
Jaffe, A.B., and A. Hall. 2005. Rho GTPases: biochemistry and biology. Annu. 
Rev.  Cell  Dev.  Biol.  21:247–269.  http://dx.doi.org/10.1146/annurev 
.cellbio.21.020604.150721
Jiang, X., and R.S. Yeung. 2006. Regulation of microtubule-dependent protein 
transport by the TSC2/mammalian target of rapamycin pathway. Cancer 
Res. 66:5258–5269. http://dx.doi.org/10.1158/0008-5472.CAN-05-4510
Julien, L.A., A. Carriere, J. Moreau, and P.P. Roux. 2010. mTORC1-activated 
S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 
signaling. Mol. Cell. Biol. 30:908–921. http://dx.doi.org/10.1128/MCB 
.00601-09
Kamada, Y., U.S. Jung, J. Piotrowski, and D.E. Levin. 1995. The protein kinase 
C-activated MAP kinase pathway of Saccharomyces cerevisiae medi-
ates a novel aspect of the heat shock response. Genes Dev. 9:1559–1571. 
http://dx.doi.org/10.1101/gad.9.13.1559
Kamada, Y., H. Qadota, C.P. Python, Y. Anraku, Y. Ohya, and D.E. Levin. 1996. 
Activation of yeast protein kinase C by Rho1 GTPase. J. Biol. Chem. 
271:9193–9196. http://dx.doi.org/10.1074/jbc.271.16.9193
Kamada, Y., Y. Fujioka, N.N. Suzuki, F. Inagaki, S. Wullschleger, R. Loewith, 
M.N. Hall, and Y. Ohsumi. 2005. Tor2 directly phosphorylates the AGC 
kinase Ypk2 to regulate actin polarization. Mol. Cell. Biol. 25:7239–7248. 
http://dx.doi.org/10.1128/MCB.25.16.7239-7248.2005
Kamimura,  Y.,  Y.  Xiong,  P.A.  Iglesias,  O.  Hoeller,  P.  Bolourani,  and  P.N. 
Devreotes.  2008.  PIP3-independent  activation  of  TorC2  and  PKB  at 
the cell’s leading edge mediates chemotaxis. Curr. Biol. 18:1034–1043. 
http://dx.doi.org/10.1016/j.cub.2008.06.068
Kantidakis, T., B.A. Ramsbottom, J.L. Birch, S.N. Dowding, and R.J. White. 
2010. mTOR associates with TFIIIC, is found at tRNA and 5S rRNA 
genes,  and  targets  their  repressor  Maf1.  Proc.  Natl.  Acad.  Sci.  USA. 
107:11823–11828. http://dx.doi.org/10.1073/pnas.1005188107
Khandoga, A., J.S. Kessler, M. Hanschen, A.G. Khandoga, D. Burggraf, C. 
Reichel, G.F. Hamann, G. Enders, and F. Krombach. 2006. Matrix metal-
loproteinase-9 promotes neutrophil and T cell recruitment and migration 
in the postischemic liver. J. Leukoc. Biol. 79:1295–1305. http://dx.doi 
.org/10.1189/jlb.0805468
Choi, J.H., N.R. Adames, T.F. Chan, C. Zeng, J.A. Cooper, and X.F. Zheng. 
2000. TOR signaling regulates microtubule structure and function. Curr. 
Biol. 10:861–864. http://dx.doi.org/10.1016/S0960-9822(00)00599-6
Citri, A., and Y. Yarden. 2006. EGF-ERBB signalling: towards the systems level. 
Nat. Rev. Mol. Cell Biol. 7:505–516. http://dx.doi.org/10.1038/nrm1962
Dada, S., N. Demartines, and O. Dormond. 2008. mTORC2 regulates PGE2-
mediated endothelial cell survival and migration. Biochem. Biophys. Res. 
Commun. 372:875–879. http://dx.doi.org/10.1016/j.bbrc.2008.05.154
Daniel,  C.,  J.  Pippin,  S.J.  Shankland,  and  C.  Hugo.  2004.  The  rapamycin   
derivative  RAD  inhibits  mesangial  cell  migration  through  the  CDK- 
inhibitor p27KIP1. Lab. Invest. 84:588–596. http://dx.doi.org/10.1038/ 
labinvest.3700078
Das, G., A. Shiras, K. Shanmuganandam, and P. Shastry. 2011. Rictor regu-
lates  MMP-9  activity  and  invasion  through  Raf-1-MEK-ERK  signal-
ing pathway in glioma cells. Mol. Carcinog. 50:412–423. http://dx.doi 
.org/10.1002/mc.20723
Denicourt, C., and S.F. Dowdy. 2004. Cip/Kip proteins: more than just CDKs in-
hibitors. Genes Dev. 18:851–855. http://dx.doi.org/10.1101/gad.1205304
Dibble,  C.C.,  J.M.  Asara,  and  B.D.  Manning.  2009.  Characterization  of 
Rictor phosphorylation sites reveals direct regulation of mTOR com-
plex  2  by  S6K1.  Mol.  Cell.  Biol.  29:5657–5670.  http://dx.doi.org/10 
.1128/MCB.00735-09
Eddy, R.J., L.M. Pierini, and F.R. Maxfield. 2002. Microtubule asymmetry dur-
ing neutrophil polarization and migration. Mol. Biol. Cell. 13:4470–4483. 
http://dx.doi.org/10.1091/mbc.E02-04-0241
Fadri, M., A. Daquinag, S. Wang, T. Xue, and J. Kunz. 2005. The pleckstrin ho-
mology domain proteins Slm1 and Slm2 are required for actin cytoskele-
ton organization in yeast and bind phosphatidylinositol-4,5-bisphosphate 
and TORC2. Mol. Biol. Cell. 16:1883–1900. http://dx.doi.org/10.1091/
mbc.E04-07-0564
Ferguson, G.J., L. Milne, S. Kulkarni, T. Sasaki, S. Walker, S. Andrews, T. 
Crabbe, P. Finan, G. Jones, S. Jackson, et al. 2007. PI(3)Kgamma has an 
important context-dependent role in neutrophil chemokinesis. Nat. Cell 
Biol. 9:86–91. http://dx.doi.org/10.1038/ncb1517
Ferrara, N. 2002. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. 
Cancer. 2:795–803. http://dx.doi.org/10.1038/nrc909
Fonseca, B.D., E.M. Smith, V.H. Lee, C. MacKintosh, and C.G. Proud. 2007. 
PRAS40 is a target for mammalian target of rapamycin complex 1 and 
is required for signaling downstream of this complex. J. Biol. Chem. 
282:24514–24524. http://dx.doi.org/10.1074/jbc.M704406200
Friedl, P., and K. Wolf. 2010. Plasticity of cell migration: a multiscale tuning 
model. J. Cell Biol. 188:11–19. http://dx.doi.org/10.1083/jcb.200909003
Gan, X., J. Wang, B. Su, and D. Wu. 2011. Evidence for direct activation of 
mTORC2  kinase  activity  by  phosphatidylinositol  3,4,5-trisphosphate.   
J.  Biol.  Chem.  286:10998–11002.  http://dx.doi.org/10.1074/jbc.M110 
.195016
Garami,  A.,  F.J.  Zwartkruis,  T.  Nobukuni,  M.  Joaquin,  M.  Roccio,  H. 
Stocker,  S.C.  Kozma,  E.  Hafen,  J.L.  Bos,  and  G.  Thomas.  2003. 
Insulin  activation  of  Rheb,  a  mediator  of  mTOR/S6K/4E-BP  signal-
ing, is inhibited by TSC1 and 2. Mol. Cell. 11:1457–1466. http://dx.doi 
.org/10.1016/S1097-2765(03)00220-X
García-Martínez, J.M., and D.R. Alessi. 2008. mTOR complex 2 (mTORC2) 
controls hydrophobic motif phosphorylation and activation of serum- and 
glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 416:375–
385. http://dx.doi.org/10.1042/BJ20081668
Gomez-Cambronero,  J.  2003.  Rapamycin  inhibits  GM-CSF-induced  neu-
trophil  migration.  FEBS  Lett.  550:94–100.  http://dx.doi.org/10.1016/ 
S0014-5793(03)00828-7
Guba, M., P. von Breitenbuch, M. Steinbauer, G. Koehl, S. Flegel, M. Hornung, 
C.J. Bruns, C. Zuelke, S. Farkas, M. Anthuber, et al. 2002. Rapamycin 
inhibits primary and metastatic tumor growth by antiangiogenesis: in-
volvement of vascular endothelial growth factor. Nat. Med. 8:128–135. 
http://dx.doi.org/10.1038/nm0202-128
Guertin, D.A., D.M. Stevens, C.C. Thoreen, A.A. Burds, N.Y. Kalaany, J. Moffat, 
M. Brown, K.J. Fitzgerald, and D.M. Sabatini. 2006. Ablation in mice of 
the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 
is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. 
Cell. 11:859–871. http://dx.doi.org/10.1016/j.devcel.2006.10.007
Gundersen, G.G., and J.C. Bulinski. 1988. Selective stabilization of micro-
tubules oriented toward the direction of cell migration. Proc. Natl. Acad. 
Sci. USA. 85:5946–5950. http://dx.doi.org/10.1073/pnas.85.16.5946
Haghighat, A., S. Mader, A. Pause, and N. Sonenberg. 1995. Repression of cap-
dependent translation by 4E-binding protein 1: competition with p220 for 
binding to eukaryotic initiation factor-4E. EMBO J. 14:5701–5709.
Heasman, S.J., and A.J. Ridley. 2008. Mammalian Rho GTPases: new insights 
into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol. 9:690–
701. http://dx.doi.org/10.1038/nrm2476823 TOR signaling during migration • Liu and Parent
for tuberous sclerosis and cancer pathogenesis. Cell. 121:179–193. http://
dx.doi.org/10.1016/j.cell.2005.02.031
Marston, D.J., and B. Goldstein. 2006. Actin-based forces driving embryonic 
morphogenesis  in  Caenorhabditis  elegans.  Curr.  Opin.  Genet.  Dev. 
16:392–398. http://dx.doi.org/10.1016/j.gde.2006.06.002
Masri, J., A. Bernath, J. Martin, O.D. Jo, R. Vartanian, A. Funk, and J. Gera. 
2007. mTORC2 activity is elevated in gliomas and promotes growth and 
cell motility via overexpression of rictor. Cancer Res. 67:11712–11720. 
http://dx.doi.org/10.1158/0008-5472.CAN-07-2223
McDonald, P.C., A. Oloumi, J. Mills, I. Dobreva, M. Maidan, V. Gray, E.D. 
Wederell, M.B. Bally, L.J. Foster, and S. Dedhar. 2008. Rictor and integrin- 
linked kinase interact and regulate Akt phosphorylation and cancer cell 
survival.  Cancer  Res.  68:1618–1624.  http://dx.doi.org/10.1158/0008-
5472.CAN-07-5869
McMahon, L.P., K.M. Choi, T.A. Lin, R.T. Abraham, and J.C. Lawrence Jr. 
2002. The rapamycin-binding domain governs substrate selectivity by the 
mammalian target of rapamycin. Mol. Cell. Biol. 22:7428–7438. http://
dx.doi.org/10.1128/MCB.22.21.7428-7438.2002
Meili, R., C. Ellsworth, and R.A. Firtel. 2000. A novel Akt/PKB-related kinase 
is essential for morphogenesis in Dictyostelium. Curr. Biol. 10:708–717. 
http://dx.doi.org/10.1016/S0960-9822(00)00536-4
Michels,  A.A.,  A.M.  Robitaille,  D.  Buczynski-Ruchonnet,  W.  Hodroj,  J.H. 
Reina, M.N. Hall, and N. Hernandez. 2010. mTORC1 directly phos-
phorylates and regulates human MAF1. Mol. Cell. Biol. 30:3749–3757. 
http://dx.doi.org/10.1128/MCB.00319-10
Montell, D.J. 2006. The social lives of migrating cells in Drosophila. Curr. Opin. 
Genet. Dev. 16:374–383. http://dx.doi.org/10.1016/j.gde.2006.06.010
Mora, A., D. Komander, D.M. van Aalten, and D.R. Alessi. 2004. PDK1, the 
master regulator of AGC kinase signal transduction. Semin. Cell Dev. 
Biol. 15:161–170. http://dx.doi.org/10.1016/j.semcdb.2003.12.022
Moss, S.C., D.J. Lightell Jr., S.O. Marx, A.R. Marks, and T.C. Woods. 2010. 
Rapamycin regulates endothelial cell migration through regulation of the 
cyclin-dependent kinase inhibitor p27Kip1. J. Biol. Chem. 285:11991–
11997. http://dx.doi.org/10.1074/jbc.M109.066621
Murooka,  T.T.,  R.  Rahbar,  L.C.  Platanias,  and  E.N.  Fish.  2008.  CCL5- 
mediated T-cell chemotaxis involves the initiation of mRNA trans-
lation  through  mTOR/4E-BP1.  Blood.  111:4892–4901.  http://dx.doi 
.org/10.1182/blood-2007-11-125039
Navé, B.T., M. Ouwens, D.J. Withers, D.R. Alessi, and P.R. Shepherd. 1999. 
Mammalian target of rapamycin is a direct target for protein kinase B: 
identification of a convergence point for opposing effects of insulin and 
amino-acid deficiency on protein translation. Biochem. J. 344:427–431. 
http://dx.doi.org/10.1042/0264-6021:3440427
Palazzo,  A.F.,  C.H.  Eng,  D.D.  Schlaepfer,  E.E.  Marcantonio,  and  G.G. 
Gundersen. 2004. Localized stabilization of microtubules by integrin- 
and FAK-facilitated Rho signaling. Science. 303:836–839. http://dx.doi 
.org/10.1126/science.1091325
Parsons, J.T., A.R. Horwitz, and M.A. Schwartz. 2010. Cell adhesion: integrat-
ing cytoskeletal dynamics and cellular tension. Nat. Rev. Mol. Cell Biol. 
11:633–643. http://dx.doi.org/10.1038/nrm2957
Pearce,  L.R.,  X.  Huang,  J.  Boudeau,  R.  Pawłowski,  S.  Wullschleger,  M. 
Deak,  A.F.  Ibrahim,  R.  Gourlay,  M.A.  Magnuson,  and  D.R.  Alessi. 
2007. Identification of Protor as a novel Rictor-binding component of 
mTOR complex-2. Biochem. J. 405:513–522. http://dx.doi.org/10.1042/ 
BJ20070540
Pearce,  L.R.,  D.  Komander,  and  D.R.  Alessi.  2010.  The  nuts  and  bolts  of 
AGC protein kinases. Nat. Rev. Mol. Cell Biol. 11:9–22. http://dx.doi 
.org/10.1038/nrm2822
Pearson, R.B., P.B. Dennis, J.W. Han, N.A. Williamson, S.C. Kozma, R.E. 
Wettenhall, and G. Thomas. 1995. The principal target of rapamycin-
induced p70s6k inactivation is a novel phosphorylation site within a con-
served hydrophobic domain. EMBO J. 14:5279–5287.
Perry,  J.,  and  N.  Kleckner.  2003.  The  ATRs,  ATMs,  and  TORs  are  giant 
HEAT  repeat  proteins.  Cell.  112:151–155.  http://dx.doi.org/10.1016/ 
S0092-8674(03)00033-3
Peterson, T.R., M. Laplante, C.C. Thoreen, Y. Sancak, S.A. Kang, W.M. Kuehl, 
N.S. Gray, and D.M. Sabatini. 2009. DEPTOR is an mTOR inhibitor fre-
quently overexpressed in multiple myeloma cells and required for their 
survival. Cell. 137:873–886. http://dx.doi.org/10.1016/j.cell.2009.03.046
Poon, M., S.O. Marx, R. Gallo, J.J. Badimon, M.B. Taubman, and A.R. Marks. 
1996. Rapamycin inhibits vascular smooth muscle cell migration. J. Clin. 
Invest. 98:2277–2283. http://dx.doi.org/10.1172/JCI119038
Ratner, S., W.S. Sherrod, and D. Lichlyter. 1997. Microtubule retraction into 
the uropod and its role in T cell polarization and motility. J. Immunol. 
159:1063–1067.
Ridley,  A.J.,  M.A.  Schwartz,  K.  Burridge,  R.A.  Firtel,  M.H.  Ginsberg,  G. 
Borisy, J.T. Parsons, and A.R. Horwitz. 2003. Cell migration: integrating   
Kim, D.H., D.D. Sarbassov, S.M. Ali, J.E. King, R.R. Latek, H. Erdjument-
Bromage, P. Tempst, and D.M. Sabatini. 2002. mTOR interacts with rap-
tor to form a nutrient-sensitive complex that signals to the cell growth 
machinery.  Cell.  110:163–175.  http://dx.doi.org/10.1016/S0092-8674 
(02)00808-5
Kim, D.H., D.D. Sarbassov, S.M. Ali, R.R. Latek, K.V. Guntur, H. Erdjument-
Bromage, P. Tempst, and D.M. Sabatini. 2003. GbetaL, a positive regulator 
of the rapamycin-sensitive pathway required for the nutrient-sensitive 
interaction between raptor and mTOR. Mol. Cell. 11:895–904. http://
dx.doi.org/10.1016/S1097-2765(03)00114-X
King,  J.S.,  and  R.H.  Insall.  2009.  Chemotaxis:  finding  the  way  forward 
with  Dictyostelium.  Trends  Cell  Biol.  19:523–530.  http://dx.doi.org/ 
10.1016/j.tcb.2009.07.004
Kobayashi,  S.,  T.  Kishimoto,  S.  Kamata,  M.  Otsuka,  M.  Miyazaki,  and  H. 
Ishikura.  2007.  Rapamycin,  a  specific  inhibitor  of  the  mammalian 
target  of  rapamycin,  suppresses  lymphangiogenesis  and  lymphatic 
metastasis.  Cancer  Sci.  98:726–733.  http://dx.doi.org/10.1111/j.1349-
7006.2007.00439.x
Koltin, Y., L. Faucette, D.J. Bergsma, M.A. Levy, R. Cafferkey, P.L. Koser, R.K. 
Johnson, and G.P. Livi. 1991. Rapamycin sensitivity in Saccharomyces 
cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to 
human FK506-binding protein. Mol. Cell. Biol. 11:1718–1723.
Kriebel,  P.W.,  V.A.  Barr,  E.C.  Rericha,  G.  Zhang,  and  C.A.  Parent.  2008. 
Collective cell migration requires vesicular trafficking for chemoattrac-
tant delivery at the trailing edge. J. Cell Biol. 183:949–961. http://dx.doi 
.org/10.1083/jcb.200808105
Kuehn, H.S., M.Y. Jung, M.A. Beaven, D.D. Metcalfe, and A.M. Gilfillan. 
2011. Prostaglandin E2 activates and utilizes mTORC2 as a central 
signaling locus for the regulation of mast cell chemotaxis and media-
tor release. J. Biol. Chem. 286:391–402. http://dx.doi.org/10.1074/jbc 
.M110.164772
Kunz, J., U. Schneider, I. Howald, A. Schmidt, and M.N. Hall. 2000. HEAT 
repeats mediate plasma membrane localization of Tor2p in yeast. J. Biol. 
Chem. 275:37011–37020. http://dx.doi.org/10.1074/jbc.M007296200
Kupfer, A., D. Louvard, and S.J. Singer. 1982. Polarization of the Golgi appa-
ratus and the microtubule-organizing center in cultured fibroblasts at the 
edge of an experimental wound. Proc. Natl. Acad. Sci. USA. 79:2603–
2607. http://dx.doi.org/10.1073/pnas.79.8.2603
Kurokawa, K., and M. Matsuda. 2005. Localized RhoA activation as a require-
ment for the induction of membrane ruffling. Mol. Biol. Cell. 16:4294–
4303. http://dx.doi.org/10.1091/mbc.E04-12-1076
Laplante, M., and D.M. Sabatini. 2009. mTOR signaling at a glance. J. Cell Sci. 
122:3589–3594. http://dx.doi.org/10.1242/jcs.051011
Le Clainche, C., and M.F. Carlier. 2008. Regulation of actin assembly associated 
with protrusion and adhesion in cell migration. Physiol. Rev. 88:489–513. 
http://dx.doi.org/10.1152/physrev.00021.2007
Lee, S., C.A. Parent, R. Insall, and R.A. Firtel. 1999. A novel Ras-interacting 
protein required for chemotaxis and cyclic adenosine monophosphate 
signal relay in Dictyostelium. Mol. Biol. Cell. 10:2829–2845.
Lee, S., F.I. Comer, A. Sasaki, I.X. McLeod, Y. Duong, K. Okumura, J.R. Yates 
III, C.A. Parent, and R.A. Firtel. 2005. TOR complex 2 integrates cell 
movement during chemotaxis and signal relay in Dictyostelium. Mol. 
Biol. Cell. 16:4572–4583. http://dx.doi.org/10.1091/mbc.E05-04-0342
Liu,  L.,  F.  Li,  J.A.  Cardelli,  K.A.  Martin,  J.  Blenis,  and  S.  Huang.  2006. 
Rapamycin  inhibits  cell  motility  by  suppression  of  mTOR-mediated 
S6K1  and  4E-BP1  pathways.  Oncogene.  25:7029–7040.  http://dx.doi 
.org/10.1038/sj.onc.1209691
Liu, L., L. Chen, J. Chung, and S. Huang. 2008. Rapamycin inhibits F-actin   
reorganization and phosphorylation of focal adhesion proteins. Oncogene. 
27:4998–5010. http://dx.doi.org/10.1038/onc.2008.137
Liu, L., S. Das, W. Losert, and C.A. Parent. 2010a. mTORC2 regulates neutro-
phil chemotaxis in a cAMP- and RhoA-dependent fashion. Dev. Cell. 
19:845–857. http://dx.doi.org/10.1016/j.devcel.2010.11.004
Liu, L., Y. Luo, L. Chen, T. Shen, B. Xu, W. Chen, H. Zhou, X. Han, and S. 
Huang. 2010b. Rapamycin inhibits cytoskeleton reorganization and cell 
motility by suppressing RhoA expression and activity. J. Biol. Chem. 
285:38362–38373. http://dx.doi.org/10.1074/jbc.M110.141168
Loewith, R., E. Jacinto, S. Wullschleger, A. Lorberg, J.L. Crespo, D. Bonenfant, 
W. Oppliger, P. Jenoe, and M.N. Hall. 2002. Two TOR complexes, only 
one of which is rapamycin sensitive, have distinct roles in cell growth 
control.  Mol.  Cell.  10:457–468.  http://dx.doi.org/10.1016/S1097-2765 
(02)00636-6
Luan, F.L., R. Ding, V.K. Sharma, W.J. Chon, M. Lagman, and M. Suthanthiran. 
2003. Rapamycin is an effective inhibitor of human renal cancer meta-
stasis.  Kidney  Int.  63:917–926.  http://dx.doi.org/10.1046/j.1523-1755 
.2003.00805.x
Ma, L., Z. Chen, H. Erdjument-Bromage, P. Tempst, and P.P. Pandolfi. 2005. 
Phosphorylation and functional inactivation of TSC2 by Erk implications JCB • VOLUME 194 • NUMBER 6 • 2011   824
signals  from  front  to  back.  Science.  302:1704–1709.  http://dx.doi 
.org/10.1126/science.1092053
Roux, P.P., B.A. Ballif, R. Anjum, S.P. Gygi, and J. Blenis. 2004. Tumor-promoting 
phorbol esters and activated Ras inactivate the tuberous sclerosis tumor 
suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. 
USA. 101:13489–13494. http://dx.doi.org/10.1073/pnas.0405659101
Saci, A., L.C. Cantley, and C.L. Carpenter. 2011. Rac1 regulates the activity of 
mTORC1 and mTORC2 and controls cellular size. Mol. Cell. 42:50–61. 
http://dx.doi.org/10.1016/j.molcel.2011.03.017
Sakakibara, K., B. Liu, S. Hollenbeck, and K.C. Kent. 2005. Rapamycin in-
hibits  fibronectin-induced  migration  of  the  human  arterial  smooth 
muscle  line  (E47)  through  the  mammalian  target  of  rapamycin.  Am. 
J.  Physiol.  Heart  Circ.  Physiol.  288:H2861–H2868.  http://dx.doi 
.org/10.1152/ajpheart.00561.2004
Sarbassov, D.D., S.M. Ali, D.H. Kim, D.A. Guertin, R.R. Latek, H. Erdjument-
Bromage, P. Tempst, and D.M. Sabatini. 2004. Rictor, a novel binding 
partner of mTOR, defines a rapamycin-insensitive and raptor-independent 
pathway  that  regulates  the  cytoskeleton.  Curr.  Biol.  14:1296–1302. 
http://dx.doi.org/10.1016/j.cub.2004.06.054
Sarbassov, D.D., D.A. Guertin, S.M. Ali, and D.M. Sabatini. 2005. Phosphory-
lation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 
307:1098–1101. http://dx.doi.org/10.1126/science.1106148
Sarbassov, D.D., S.M. Ali, S. Sengupta, J.H. Sheen, P.P. Hsu, A.F. Bagley, A.L. 
Markhard, and D.M. Sabatini. 2006. Prolonged rapamycin treatment in-
hibits mTORC2 assembly and Akt/PKB. Mol. Cell. 22:159–168. http://
dx.doi.org/10.1016/j.molcel.2006.03.029
Schmidt, A., J. Kunz, and M.N. Hall. 1996. TOR2 is required for organization 
of the actin cytoskeleton in yeast. Proc. Natl. Acad. Sci. USA. 93:13780–
13785. http://dx.doi.org/10.1073/pnas.93.24.13780
Schmidt, A., M. Bickle, T. Beck, and M.N. Hall. 1997. The yeast phosphati-
dylinositol kinase homolog TOR2 activates RHO1 and RHO2 via the 
exchange  factor  ROM2.  Cell.  88:531–542.  http://dx.doi.org/10.1016/ 
S0092-8674(00)81893-0
Scott, P.H., G.J. Brunn, A.D. Kohn, R.A. Roth, and J.C. Lawrence Jr. 1998. 
Evidence  of  insulin-stimulated  phosphorylation  and  activation  of  the 
mammalian target of rapamycin mediated by a protein kinase B signal-
ing pathway. Proc. Natl. Acad. Sci. USA. 95:7772–7777. http://dx.doi 
.org/10.1073/pnas.95.13.7772
Sekulić, A., C.C. Hudson, J.L. Homme, P. Yin, D.M. Otterness, L.M. Karnitz,   
and R.T. Abraham. 2000. A direct linkage between the phosphoinosi-
tide 3-kinase-AKT signaling pathway and the mammalian target of rapa-
mycin  in  mitogen-stimulated  and  transformed  cells.  Cancer  Res.  
60:3504–3513.
Shiota, C., J.T. Woo, J. Lindner, K.D. Shelton, and M.A. Magnuson. 2006. 
Multiallelic disruption of the rictor gene in mice reveals that mTOR com-
plex 2 is essential for fetal growth and viability. Dev. Cell. 11:583–589. 
http://dx.doi.org/10.1016/j.devcel.2006.08.013
Shor, B., J. Wu, Q. Shakey, L. Toral-Barza, C. Shi, M. Follettie, and K. Yu. 2010. 
Requirement of the mTOR kinase for the regulation of Maf1 phosphory-
lation and control of RNA polymerase III-dependent transcription in can-
cer cells. J. Biol. Chem. 285:15380–15392. http://dx.doi.org/10.1074/jbc 
.M109.071639
Sofer, A., K. Lei, C.M. Johannessen, and L.W. Ellisen. 2005. Regulation 
of mTOR and cell growth in response to energy stress by REDD1. 
Mol. Cell. Biol. 25:5834–5845. http://dx.doi.org/10.1128/MCB.25.14 
.5834-5845.2005
Stephens, L., L. Milne, and P. Hawkins. 2008. Moving towards a better un-
derstanding  of  chemotaxis.  Curr.  Biol.  18:R485–R494.  http://dx.doi 
.org/10.1016/j.cub.2008.04.048
Sun, J., S.O. Marx, H.J. Chen, M. Poon, A.R. Marks, and L.E. Rabbani. 2001. 
Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation. 
103:2967–2972.
Swaney, K.F., C.H. Huang, and P.N. Devreotes. 2010. Eukaryotic chemotaxis: 
a network of signaling pathways controls motility, directional sensing, 
and polarity. Annu Rev Biophys. 39:265–289. http://dx.doi.org/10.1146/ 
annurev.biophys.093008.131228
Takahashi,  T.,  K.  Hara,  H.  Inoue,  Y.  Kawa,  C.  Tokunaga,  S.  Hidayat,  K. 
Yoshino, Y. Kuroda, and K. Yonezawa. 2000. Carboxyl-terminal region 
conserved among phosphoinositide-kinase-related kinases is indispens-
able for mTOR function in vivo and in vitro. Genes Cells. 5:765–775. 
http://dx.doi.org/10.1046/j.1365-2443.2000.00365.x
Tee,  A.R.,  B.D.  Manning,  P.P.  Roux,  L.C.  Cantley,  and  J.  Blenis.  2003. 
Tuberous  sclerosis  complex  gene  products,  Tuberin  and  Hamartin, 
control  mTOR  signaling  by  acting  as  a  GTPase-activating  pro-
tein  complex  toward  Rheb.  Curr.  Biol.  13:1259–1268.  http://dx.doi 
.org/10.1016/S0960-9822(03)00506-2
Toschi, A., E. Lee, L. Xu, A. Garcia, N. Gadir, and D.A. Foster. 2009. Regulation 
of mTORC1 and mTORC2 complex assembly by phosphatidic acid: 
competition  with  rapamycin.  Mol.  Cell.  Biol.  29:1411–1420.  http://
dx.doi.org/10.1128/MCB.00782-08
Treins, C., P.H. Warne, M.A. Magnuson, M. Pende, and J. Downward. 2010. 
Rictor is a novel target of p70 S6 kinase-1. Oncogene. 29:1003–1016. 
http://dx.doi.org/10.1038/onc.2009.401
Turner, H.E., A.L. Harris, S. Melmed, and J.A. Wass. 2003. Angiogenesis in 
endocrine tumors. Endocr. Rev. 24:600–632. http://dx.doi.org/10.1210/er 
.2002-0008
Vaillant, C., C. Meissirel, M. Mutin, M.F. Belin, L.R. Lund, and N. Thomasset. 
2003. MMP-9 deficiency affects axonal outgrowth, migration, and apop-
tosis in the developing cerebellum. Mol. Cell. Neurosci. 24:395–408. 
http://dx.doi.org/10.1016/S1044-7431(03)00196-9
Wan, X., A. Mendoza, C. Khanna, and L.J. Helman. 2005. Rapamycin inhib-
its ezrin-mediated metastatic behavior in a murine model of osteosar-
coma. Cancer Res. 65:2406–2411. http://dx.doi.org/10.1158/0008-5472 
.CAN-04-3135
Wang, F. 2009. The signaling mechanisms underlying cell polarity and che-
motaxis.  Cold  Spring  Harb.  Perspect.  Biol.  1:a002980.  http://dx.doi 
.org/10.1101/cshperspect.a002980
Wang, L., T.E. Harris, R.A. Roth, and J.C. Lawrence Jr. 2007. PRAS40 regulates 
mTORC1 kinase activity by functioning as a direct inhibitor of substrate 
binding. J. Biol. Chem. 282:20036–20044. http://dx.doi.org/10.1074/jbc 
.M702376200
Weijer,  C.J.  2009.  Collective  cell  migration  in  development.  J.  Cell  Sci. 
122:3215–3223. http://dx.doi.org/10.1242/jcs.036517
Wong, A.S., C.D. Roskelley, S. Pelech, D. Miller, P.C. Leung, and N. Auersperg. 
2004. Progressive changes in Met-dependent signaling in a human ovarian 
surface epithelial model of malignant transformation. Exp. Cell Res. 299: 
248–256. http://dx.doi.org/10.1016/j.yexcr.2004.06.002
Wong, K., A. Van Keymeulen, and H.R. Bourne. 2007. PDZRhoGEF and myosin 
II localize RhoA activity to the back of polarizing neutrophil-like cells.   
J. Cell Biol. 179:1141–1148. http://dx.doi.org/10.1083/jcb.200706167
Woo, S.Y., D.H. Kim, C.B. Jun, Y.M. Kim, E.V. Haar, S.I. Lee, J.W. Hegg, S. 
Bandhakavi, T.J. Griffin, and D.H. Kim. 2007. PRR5, a novel component 
of mTOR complex 2, regulates platelet-derived growth factor receptor 
beta expression and signaling. J. Biol. Chem. 282:25604–25612. http://
dx.doi.org/10.1074/jbc.M704343200
Wullschleger, S., R. Loewith, W. Oppliger, and M.N. Hall. 2005. Molecular   
organization of target of rapamycin complex 2. J. Biol. Chem. 280:30697–
30704. http://dx.doi.org/10.1074/jbc.M505553200
Yang, Q., K. Inoki, T. Ikenoue, and K.L. Guan. 2006a. Identification of Sin1 
as an essential TORC2 component required for complex formation and 
kinase  activity.  Genes  Dev.  20:2820–2832.  http://dx.doi.org/10.1101/ 
gad.1461206
Yang, Q., K. Inoki, E. Kim, and K.L. Guan. 2006b. TSC1/TSC2 and Rheb have 
different effects on TORC1 and TORC2 activity. Proc. Natl. Acad. Sci. 
USA. 103:6811–6816. http://dx.doi.org/10.1073/pnas.0602282103
Zhang, F., X. Zhang, M. Li, P. Chen, B. Zhang, H. Guo, W. Cao, X. Wei, X. 
Cao, X. Hao, and N. Zhang. 2010. mTOR complex component Rictor 
interacts with PKCzeta and regulates cancer cell metastasis. Cancer Res. 
70:9360–9370. http://dx.doi.org/10.1158/0008-5472.CAN-10-0207
Zhou, H.Y., and A.S. Wong. 2006. Activation of p70S6K induces expression 
of matrix metalloproteinase 9 associated with hepatocyte growth fac-
tor-mediated  invasion  in  human  ovarian  cancer  cells.  Endocrinology. 
147:2557–2566. http://dx.doi.org/10.1210/en.2005-1404
Zoncu, R., A. Efeyan, and D.M. Sabatini. 2011. mTOR: from growth signal   
integration  to  cancer,  diabetes  and  ageing.  Nat.  Rev.  Mol.  Cell  Biol. 
12:21–35. http://dx.doi.org/10.1038/nrm3025